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The age distribution of cases of dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS) in
infants under the age of 1 year are reported from Bangkok, Thailand, and for the first time for Ho Chi Minh
City, Vietnam; Yangon, Myanmar; and Surabaya, Indonesia. The four dengue viruses were isolated from
Thai infants, all of whom were having a primary dengue infection. Progress studying the immunologically
distinct infant DHF/DSS has been limited; most contemporary research has centered on DHF/DSS accom-
panying secondary dengue infections. In designing research results obtained in studies on a congruent
animal model, feline infectious peritonitis virus (FIPV) infections of kittens born to FIPV-immune queens
should be considered. Research challenges presented by infant DHF/DSS are discussed.
ince World War II, the four dengue viruses (formal name:
Dengue virus [DENV]) have progressively spread geo-
graphically throughout the tropics, resulting in a global pan-
demic with tens of millions of infections annually, including
several hundred thousand hospitalizations for dengue hemor-
rhagic fever (DHF) and dengue shock syndrome (DSS) (1).
The size and spread of the dengue pandemic, the unpredict-
ability of epidemic occurrences, and the circulation of virulent
and nonvirulent strains make DHF/DSS a model for an emerg-
ing infectious disease. 
Ample evidence suggests that DHF/DSS accompanies sec-
ondary dengue infections in children older than 1 year (1–3).
Less well-known are the epidemiologic and clinical studies
that document an identical severe syndrome in infants during
their first dengue infection (4,5). Ignoring these data, contem-
porary models of dengue immunopathogenesis focus on the
sequential dengue viral infection phenomenon; such models
suggest that severe disease results from amplified cytokine
release caused by dengue infections occurring in the presence
of T-cell memory (6). However, that model cannot explain
DHF/DSS during a first dengue infection. 
That dengue in infants is not often studied is understand-
able. Small subjects pose technical difficulties in obtaining
samples required by research protocols, and human use proto-
cols may be constraining. Yet infants represent 5% or more of
all DHF/DSS patients (7). Uniquely, infants with DHF/DSS
present an opportunity to obtain both the causative virus and
the preinfection antibodies as research reagents in a hospital
setting without recourse to a time-consuming and expensive
prospective cohort study. The all-important preinfection anti-
bodies can be collected from the mother, as her serum is a sur-
rogate for cord blood (8). 
Enhancement of infant infectious diseases by cord blood
antibodies is not described for human infections other than
dengue. However, such a phenomenon occurs naturally in
infected kittens born to queens immune to feline infectious
peritonitis virus (FIPV) (9–11). To refocus attention on the
research opportunities afforded by this immunopathologic
entity, we provide evidence that infants with DHF/DSS are
regularly admitted to hospitals in four of the largest dengue-
endemic countries. The age distribution of all these infant
DHF/DSS patients is similar. Most of those studied serologi-
cally had had primary dengue infections. Because of FIPV’s
congruence to infant dengue, a short literature review is pro-
vided on that animal model. 
Materials and Methods
Patients
Data on infants, ages <12 months, hospitalized with a clin-
ical diagnosis of DHF were obtained from four hospitals: Chil-
dren’s Hospital No. 1, Ho Chi Minh City, Vietnam; the Queen
Sirikit National Institute of Child Health, also referred to as
Bangkok Children’s Hospital, Bangkok, Thailand; Children’s
Hospital, Yangon, Myanmar; and the Department of Pediat-
rics, Dr. Soetomo Hospital, Surabaya, Indonesia. In this study,
data for 4 consecutive years, either 1995–1998 or 1996–1999
were combined. Patients were under the routine care of one or
more of the authors, each an experienced senior academic
infectious diseases pediatrician. All diagnoses of DHF/DSS in
infants conformed to World Health Organization case defini-
tions. In Bangkok, serum samples from all infants and children
hospitalized for DHF were sent for routine diagnostic study to
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the Virology Department, Armed Forces Research Institute of
Medical Sciences (AFRIMS). For nearly 30 years, AFRIMS
has provided such dengue diagnostic services to Bangkok
Children’s Hospital. Similar routine diagnostic tests were pro-
vided for infants and children admitted to Children’s Hospital,
Yangon, by the Virology Department, Department of Medical
Research. Fiscal constraints limited the number of serologic
tests performed. Individual data were disassociated from any
identifiers and are presented here only in aggregate.
Virus Isolation
As described, DENV isolations were attempted from
acute-phase plasma or serum samples from Thai children by
inoculation into C6/36 cells or intrathoracically in mosquitoes
(Toxorrhynchites splendens) (12).
Viral Identification
DENV was identified in C6/36 cells by an antigen-specific
enzyme-linked immunosorbent assay (ELISA) with a panel of
monoclonal antibodies against DENV (13). 
Serology
Plasma or serum samples were tested for serologic evi-
dence of acute DENV infection by immunoglobulin (Ig) M
and IgG ELISA, hemagglutination inhibition (HAI) assays, or
both (14). For single specimens, >5 days after onset of fever
40 U of IgM to DENV was considered evidence of a DENV
infection. A DENV IgM-to-IgG ratio >1.8 defined a primary
infection. A ratio <1.8 defined a secondary DENV infection.
With serial specimens, twofold increase in IgG to DENV with
an absolute value of >100 U indicated a secondary infection in
the absence of IgM to DENV of >40 U.
In Bangkok, HAI antibody against DENV types 1–4 and
Japanese encephalitis virus were measured in all sera (15). A
fourfold increase was considered positive for acute flavivirus
infection. The infection was diagnosed as primary if titers >1
week after onset of illness were <1:1,280 or as secondary if
antibody titers were >1:1,280 (16). 
Results
Infants are at high risk for DHF/DSS. Figure 1 provides
data from the only published study to estimate age-specific
dengue hospitalization rates for the Bangkok metropolitan
area. In 1964, 17/1,000 seven-month-old infants, more than
1% of the population that age, were hospitalized for DHF/DSS
(17). This modal rate was two times higher than the 1964
modal hospitalization rate for children (age 4 years, data not
shown) in Bangkok during the same year (17). In our present
study, infant DHF/DSS constituted 4.9%, 4.6%, 5.0%, and
4.9% of 4,872; 14,053; 8,938; and 2,057 Thai, Vietnamese,
Myanmar, and Indonesian infants and children hospitalized
with DHF in 1995–1998, respectively. 
During a 4-year period, 237, 652, 449, and 101 infants
with presumptive DHF/DSS were admitted to hospitals in
Bangkok, Ho Chi Minh City, Yangon, and Surabaya. No sig-
nificant differences in age distributions were observed year to
year (data not shown). Data for 4 years were combined to
smooth age distributions (Figure 2). Among infants hospital-
ized at Bangkok Children’s Hospital, the distribution of World
Health Organization grades 1, 2, 3, and 4 was 16.4, 56.2, 23.9,
and 3.0%, respectively. Only 2 of 220 infants whose serum
samples were tested had a secondary-type antibody response,
97.5% had primary infections. DENV was isolated from 114
(nearly 50%) of Thai infants; DENV types 1, 2, 3, 4 were
recovered from 34, 23, 56, and 1 infant, respectively. Nineteen
Myanmar infants were serologically confirmed as having a
recent primary infection; seven, mostly infants >10 months of
age, had secondary-type dengue HAI-antibody responses. 
The distribution by age of DHF/DSS infants in all four
countries presents a similar pattern: few cases were observed
in infants younger than 3 months, and the largest numbers
observed were in infants 6–8 months old. Later in the first
Figure 1. Age-specific hospitalization rates/1,000 infants with dengue
hemorrhagic fever/dengue shock syndrome, Bangkok, Thailand, 1962–
1964. Source: Halstead SB, et al. Am J Trop Med Hyg (17); cited with
permission.
Figure 2. Month of age of infants hospitalized for dengue hemorrhagic
fever/dengue shock syndrome at the Bangkok Children’s Hospital,
1995–1998 (Thailand), Children’s Hospital No.1, Ho Chi Minh City,
1995–1998 (Vietnam), Yangon Children’s Hospital, 1995–1998 (Myan-
mar) and Dr. Soetomo Hospital, Surabaya, 1996–1999 (Indonesia).
Data are combined for the period shown.PERSPECTIVE
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year, admissions declined nearly to baseline in Thailand and
Indonesia. In Yangon, the decline in admissions reversed at
age 10 months and increased. In Yangon, DHF hospitalizations
continued to increase during the second year of life (Figure 3).
In Ho Chi Minh City, cases in 11-month-olds declined, but not
quite to the baseline.
Children hospitalized with DHF/DSS in Bangkok show the
classical bimodal curve: relatively few cases in children 12–24
months of age and a modal age later in life, in this case at 8
years of age (Figure 4). By contrast, this bimodal distribution
is not present in Yangon. DHF/DSS occurs commonly in 12-
to 24-month-old children, and the modal age at admission is 4
years (Figure 3). 
Discussion
The patterns of age distribution of infant DHF/DSS were
similar in four large Southeast Asian countries highly endemic
for all four DENV serotypes. Nearly all infants in the large
Thai and most in the smaller Myanmar groups had primary
DENV antibody responses. The characteristic and unique age-
specific hospitalization curves are consistent with published
observations that describe infant DHF/DSS occurrence during
primary DENV infections. Primary and secondary DHF infec-
tions are reconciled in a long-standing explanatory hypothesis
linking severe disease to actively or passively acquired anti-
bodies (4,8,18). In our study, infants constituted approximately
5% of total DHF/DSS patients, lower than the nearly 10%
reported from Bangkok Children’s Hospital in the 1960s
(7,17). 
Differences were observed in the age distribution curves in
Yangon and Ho Chi Minh City compared with Bangkok and
Surabaya. In Yangon, the curve declined at 8 months but rose
again at age 10 months, and no dip in cases occurred in 1-year-
old children (Figures 2 and 3). In Ho Chi Minh City, infant
cases declined at the end of the first year of life, but not to the
baseline; by contrast, in Thailand and Indonesia by the end of
the first year of life, the curve approached the baseline. These
phenomena may be explained by differences in average annual
rates of dengue infection. In Yangon, the modal age of hospi-
talization for DHF/DSS for children is 4 years (Figure 3),
while in Bangkok it is 8 years (Figure 4). In Bangkok, DHF/
DSS is rarely seen in 12- to 24-month-olds, signifying that
second infections are usually delayed until after a child has
lived through two dengue transmission periods (Figure 4).
Among serologically studied infant DHF/DSS patients in
Yangon, several ages 10 months and older had secondary den-
gue infections. These observations are consistent with high
average annual rates of dengue infection in Yangon and lower
infection rates in Bangkok. These relationships have been
modeled mathematically (19). 
Since infant DHF/DSS was first reported in 1970 (4), only
a single research study has been undertaken on this group (8).
This study included 13 Bangkok infants, all with primary
DENV-2 infections, who were admitted to hospital at different
ages in the first year of life. During hospitalization, mother’s
blood was taken and tested as a surrogate for cord blood at
birth. An analysis of dengue-neutralizing antibodies showed
that every mother in the study had had two or more previous
DENV infections (8). All infants acquired DHF/DSS during
the short window of time when maternal DENV-2 neutralizing
antibodies had degraded to a titer of approximately 1:10.
Maternal sera enhanced DENV-2 at high dilutions. These data
provide a logical explanation for the observed age distribution
of infant DHF/DSS. At birth, maternal antibodies protect
infants from dengue infection. As IgG antibodies are catabo-
lized, a period of risk to enhanced infection ensues, followed
in turn by the loss of enhancing antibodies and a correspond-
ing decline in risk for DHF/DSS (Figure 5). 
Data from studies on infants as well as prospective cohort
studies on children demonstrate that the waning or absence of
heterotypic neutralizing antibodies permits enhanced infec-
tions to occur. Infection enhancement occurs at lower antibody
concentrations than neutralization (8,20). 
Figure 3. Year of age at hospitalization of children with dengue hemor-
rhagic fever/dengue shock syndrome, Yangon Children’s Hospital,
Yangon, Myanmar, 1995–1998, combined.
Figure 4. Year of age of children hospitalized for dengue hemorrhagic
fever/dengue shock syndrome at Bangkok Children’s Hospital,
Bangkok, Thailand, 1990–1999, combined.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1477
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Immunopathogenesis mechanisms have been more exten-
sively studied in a remarkably similar viral infection of cats,
FIPV, a highly fatal coronavirus disease of domestic and exotic
cats (9–11). Most cats naturally exposed as adults to FIPV
develop antibody titers without showing clinical signs.
Lesions in sick cats are believed to result from immunologi-
cally mediated responses (9,10,21). Kittens receiving appar-
ently competent neutralizing antibodies to FIPV, transferred in
colostrum from immune queens, develop a fatal disease a few
days after infection with wild-type virus (22). Passive transfer
of antibody by other routes produces the same result (22,23).
This phenomenon is called the early death syndrome. FIPV in
antibody-negative kittens occurs less reliably and is delayed
for several weeks until animals develop their own antibody
response to the virus. FIPV in kittens is characterized by
thrombocytopenia and elevated ALT, AST, and serum biliru-
bin (22).
The coronaviruses, pathogens of mammals and birds, are a
large family of enveloped RNA viruses with a nonsegmented,
positive-stranded genome that is 27–32 kb in length (24). One
of the most intriguing aspects of coronavirus replication is the
occurrence of high-frequency homologous RNA recombina-
tion (25). Together with porcine Transmissible gastroenteritis
virus (TGEV), canine coronavirus, and human coronavirus
229E (HCV), the feline coronaviruses form a separate cluster
within the genus Coronavirus, including Feline enteric coro-
navirus, and FIPV (26). Coronavirus virions possess three
structural proteins, a large spike glycoprotein (S), a small inte-
gral membrane glycoprotein (M), and a nucleocapsid protein
(N) (24). These proteins are analogous to the envelope (E), M,
and nucleocapsid (C) proteins of the flaviviruses. The feline
coronaviruses can be divided into two serotypes, I and II, on
the basis of cross-reactivity to canine coronavirus in virus neu-
tralization assays (26). Type I viruses grow poorly in tissue
cultures and show virtually no neutralization with anti–canine
coronavirus sera (27). Type II viruses grow readily in vitro
(28). Analysis of gene structure suggests that type II viruses
are derived from recombination of type I feline coronavirus
and canine coronavirus (26). The two serotypes circulate as
two pathotypes, the avirulent enteric viruses and the virulent
FIPV (26). High-frequency mutations may help coronaviruses
escape neutralization and promote infection enhancement in
Fc receptor–bearing cells.
Antibody-dependent enhancement of FIPV has been dem-
onstrated in vitro in feline macrophages as well as in stable
human and mouse macrophage cell lines (29). More cells are
infected in the presence compared with the absence of anti-
body; the rates of viral entry and viral replication are similar
under both conditions (30). Coronaviruses appear to enter
mononuclear phagocytes by means of the plasma membrane
without marked involvement of phagocytic or endosomal
pathways (28). Some researchers have surmised that, as with
DENV, when antibody-virus complexes attach to Fc-receptors,
viruses are brought close to cell surfaces, where they enter the
cells by normal mechanisms (31,32). Enhancement is medi-
ated by clusters of epitopes on the S protein (33,34). Results
with FIPV suggest that feline IgG2a antibodies mediate both
neutralization and enhancement (33). Antibody-dependent
enhancement in FIPV demonstrates a bell-shaped curve with
increasing dilutions; maximal enhancement occurs at subneu-
tralizing titers (34). 
Antibody-dependent enhancement is believed to be the
cause of vaccine failure after immunization with live (35,36)
or recombinant (37) vaccines. Inoculation of cats with a
recombinant vaccinia virus expressing the S protein FIPV 79-
1146 sensitized cats and led to accelerated disease after FIPV
challenge (37), while inoculation with recombinant vaccinia
viruses expressing the M or N proteins did not (38). Immuni-
zation with vaccines made from other members of the feline
coronavirus group, TGEV or canine coronavirus, also sensi-
tizes cats to early death syndrome (39). 
Flaviviridae do not appear to be subject to as high rates of
homologous recombination as are the Coronaviridae; nonethe-
less, during evolutionary history four dengue serotypes have
emerged. A phenomenon reminiscent of the feline coronavi-
ruses is the evidence that DENV also circulate as two bio-
types: DENV-2 American genotype does not cause DHF/DSS,
while DENV-2 SE Asian genotype does (40). As with feline
coronaviruses, the severity of disease with the two DENV bio-
types may be regulated by cross-reactive antibodies (41).
Focused research on viral-antibody interactions at the struc-
tural level might clarify early pathogenesis events in DHF/
DSS. Infants may provide an accessible and inexpensive
model to study mechanisms controlling the severity of dengue
infections. Workers actively involved in developing dengue
vaccines may benefit from lessons learned in the FIPV model.
Figure 5. Relationship between the age distributions of infants hospital-
ized for dengue hemorrhagic fever/dengue shock syndrome (DHF/
DSS) and the protective and infection-enhancing effects of maternal
dengue antibodies. Shown are mean age specific hospitalization rate/
1,000 for Bangkok and Thonburi, 1962–1964 (see Figure 1). At birth,
antibodies are at protective concentrations. With the passage of time,
maternal immunoglobulin G antibodies are catabolized to concentra-
tions that result in antibody-dependent enhancement (ADE) of infec-
tions. By the end of the first year of life, ADE antibodies are catabolized
to concentrations below the ADE threshold, and DHF/DSS cases disap-
pear.PERSPECTIVE
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